- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout | 12 | FierceBiotech | ||
| 14.01. | Kiniksa Pharmaceuticals beruft neuen COO und Chief Strategy Officer | - | Investing.com Deutsch | ||
| 12.01. | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | - | SEC Filings | ||
| 12.01. | Kiniksa Pharmaceuticals sees ARCALYST net product revenue between $900M-$920M for 2026 | 3 | Seeking Alpha | ||
| 12.01. | Kiniksa reports 62% growth in ARCALYST revenue, forecasts 2026 sales | 2 | Investing.com | ||
| KINIKSA PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 12.01. | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Provides Corporate Update | 316 | GlobeNewswire (Europe) | - ARCALYST- (rilonacept) 2025 net product revenue of $677.5 million (unaudited), representing ~62% year-over-year growth -- ARCALYST 2026 net product revenue expected to be $900 - $920 million --... ► Artikel lesen | |
| 22.12.25 | Why Analysts Favor Kiniksa Pharmaceuticals (KNSA) | 3 | Insider Monkey | ||
| 18.11.25 | Aktie von Kiniksa Pharmaceuticals erreicht Rekordhoch von 42,11 USD | 5 | Investing.com Deutsch | ||
| 28.10.25 | Kiniksa Pharmaceuticals International, plc - 10-Q, Quarterly Report | 6 | SEC Filings | ||
| 28.10.25 | Kiniksa raises 2025 ARCALYST sales guidance to $670M-$675M as market penetration grows | 6 | Seeking Alpha | ||
| 28.10.25 | Kiniksa Pharmaceuticals International, plc - 8-K, Current Report | 1 | SEC Filings | ||
| 28.10.25 | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution | 252 | GlobeNewswire (Europe) | - ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth -- ARCALYST 2025 expected net product revenue raised to $670 - $675 million -- KPL-387... ► Artikel lesen | |
| 27.10.25 | What to Expect from Kiniksa Pharmaceuticals' Earnings | 10 | Benzinga.com | ||
| 27.10.25 | Kiniksa Pharmaceuticals International, plc Q3 2025 Earnings Preview | 2 | Seeking Alpha | ||
| 22.10.25 | Kiniksa stock price target maintained at $60 by TD Cowen on strong Arcalyst sales | 1 | Investing.com | ||
| 22.10.25 | TD Cowen bestätigt Kursziel für Kiniksa bei 60 Dollar - Starke Arcalyst-Umsätze als Treiber | 3 | Investing.com Deutsch | ||
| 17.10.25 | 5 Analysts Have This To Say About Kiniksa Pharmaceuticals | 1 | Benzinga.com | ||
| 17.10.25 | Kiniksa Pharmaceuticals Says FDA Grants Orphan Drug Designation For KPL-387 To Treat Pericarditis | 1 | RTTNews | ||
| 17.10.25 | FDA erteilt Kiniksa Orphan-Drug-Status für Medikament gegen Perikarditis | 22 | Investing.com Deutsch | ||
| 17.10.25 | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Announces U.S. Orphan Drug Designation for KPL-387 for the Treatment of Pericarditis | 319 | GlobeNewswire (Europe) | LONDON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases... ► Artikel lesen |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 95,80 | -0,21 % | Pharma- und Biotech-Aktien 2026: Bayer und BioNTech geben Gas, Bioxyne vor Durchbruch? | ||
| BB BIOTECH | 50,60 | -0,20 % | BB Biotech und HBM Healthcare: Erfreulicher Zahlenreigen | ||
| MODERNA | 36,760 | -1,17 % | Moderna, Inc.: Dr. David Berman to Join Moderna as Chief Development Officer | CAMBRIDGE, MASSACHUSETTS / ACCESS Newswire / January 30, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that David Berman, M.D., Ph.D. has been appointed as the Company's Chief Development Officer... ► Artikel lesen | |
| AMGEN | 288,20 | -0,10 % | Amgen, Kyowa Kirin End Collaboration On Atopic Dermatitis Drug Rocatinlimab | THOUSAND OAKS (dpa-AFX) - Kyowa Kirin Co., Ltd. (KYKOY) said on Friday it has ended its development and commercialization partnership with Amgen for rocatinlimab, with the Japanese drugmaker... ► Artikel lesen | |
| NOVAVAX | 7,437 | -0,34 % | NOVAVAX INC: Schwäche mit Signalwirkung | ||
| BIOGEN | 149,10 | +1,19 % | Biogen Says FDA Grants Breakthrough Therapy Designation For Litifilimab To Treat CLE | WESTON (dpa-AFX) - Biogen, Inc. (BIIB) announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 626,80 | +0,16 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q4 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) announced a profit for fourth quarter that Drops, from the same period last yearThe company's earnings totaled $844.6 million, or... ► Artikel lesen | |
| MAINZ BIOMED | 1,200 | -1,64 % | EQS-News: Mainz BioMed N.V.: Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung 2026 | Emittent / Herausgeber: Mainz BioMed N.V.
/ Schlagwort(e): Konferenz
Mainz Biomed präsentiert Ergebnisse einer Verifizierungsstudie zu Bauchspeicheldrüsenkrebs auf der AACR-Jahrestagung... ► Artikel lesen | |
| VIKING THERAPEUTICS | 24,780 | +1,02 % | Eli Lilly or Viking Therapeutics: Which Stock Is More Likely to be a Millionaire-Maker? | ||
| INTELLIA THERAPEUTICS | 11,105 | +0,14 % | Weekly Buzz: Intellia Gets FDA Nod For ATTRv-PN Trial; Aprea's APR-1051 Paces; CALC Halts KOURAGE | SOUTH SAN FRANCISCO (dpa-AFX) - This week's biotech landscape features key FDA approvals, clinical holds and go-aheads, trial discontinuations, and clinical trial data readouts across key therapeutic... ► Artikel lesen | |
| TEMPUS AI | 51,00 | +0,99 % | Studie von Tempus AI belegt verbesserte Vorhersage für Krebs-Immuntherapie | ||
| BIOCRYST PHARMACEUTICALS | 5,586 | +0,68 % | BioCryst Pharmaceuticals, Inc.: BioCryst Completes Acquisition of Astria Therapeutics, Expanding Leadership in Hereditary Angioedema | RESEARCH TRIANGLE PARK, N.C., Jan. 23, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that it has completed its acquisition of Astria Therapeutics, Inc., initially... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 47,360 | -0,73 % | BioMarin Pharmaceutical Inc.: BioMarin Announces Pricing of Private Offering of Senior Notes and Completion of Syndication of New Senior Secured Term Loan Facility | SAN RAFAEL, Calif., Jan. 29, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ("BioMarin") announced today that it priced its previously announced... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,230 | +0,44 % | SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,933 | +1,65 % | PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026 |
KINIKSA PHARMACEUTICALS INTERNATIONAL PLC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,14 % bei einem Aktienkurs von 43,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu KINIKSA PHARMACEUTICALS INTERNATIONAL PLC finden Sie auf Wallstreet Online.